BDMC-A

BDMC-A is a **synthetic analog of curcumin**, specifically a bisdemethoxycurcumin analog, lacking the methoxy groups present in curcumin and designed to enhance stability and biological activity. It retains the **core diarylpentanoid structure** of curcumin[2]. BDMC-A exhibits **antitumor, antimutagenic, and antioxidant properties** and has been demonstrated in preclinical studies to induce **apoptosis** and inhibit **invasion, angiogenesis, and metastasis** in cancer models, particularly in human laryngeal cancer (Hep-2) cells. Mechanistically, BDMC-A inhibits key transcription factors involved in tumor progression, including **NF-κB-p65, c-Jun, c-Fos, STAT3, STAT5, PPAR-γ, and β-catenin**. It also downregulates **MMP-9, VEGF, IL-6, and IL-8**, and upregulates **TIMP-2**, contributing to its anti-invasive and anti-metastatic effects[1]. BDMC-A has been compared favorably to curcumin for cancer-related endpoints, but is not an approved pharmaceutical, being primarily studied as a research chemical and dietary supplement ingredient[1][5].

Other names

bisdemethoxycurcumin analog